as of 03-10-2026 3:34pm EST
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
| Founded: | 2002 | Country: | France |
| Employees: | 90 | City: | CHATILLON |
| Market Cap: | 1.1B | IPO Year: | 2014 |
| Target Price: | $31.75 | AVG Volume (30 days): | 186.8K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.82 | EPS Growth: | -53.95 |
| 52 Week Low/High: | $3.91 - $26.18 | Next Earning Date: | N/A |
| Revenue: | $4,151,000 | Revenue Growth: | -73.61% |
| Revenue Growth (this year): | 65.5% | Revenue Growth (next year): | 47.02% |
| P/E Ratio: | -26.98 | Index: | N/A |
| Free Cash Flow: | -106812000.0 | FCF Growth: | N/A |
Chief Medical Officer
Avg Cost/Share
$4.86
Shares
534
Total Value
$2,595.24
Owned After
144,995
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Mohideen Pharis | DBVT | Chief Medical Officer | Jan 29, 2026 | Sell | $4.86 | 534 | $2,595.24 | 144,995 |
SEC 8-K filings with transcript text
Oct 29, 2025 · 100% conf.
1D
-0.05%
$15.20
5D
-6.75%
$14.18
20D
+49.18%
$22.69
8-K
00-0000000 true 0001613780 false 0001613780 2025-10-28 2025-10-28 0001613780 us-gaap:CommonStockMember 2025-10-28 2025-10-28 0001613780 dei:AdrMember 2025-10-28 2025-10-28
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 28, 2025 Date of Report (Date of earliest event reported)
DBV Technologies S.A. (Exact name of registrant as specified in its charter)
France
001-36697
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
107 avenue de la République 92320 Châtillon France
Not Applicable
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: +33 1 55 42 78 78
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary shares, nominal value €0.10 per share
n/a
The Nasdaq Stock Market LLC *
American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share
The Nasdaq Stock Market LLC
* Not for trading, but only in connection with the registration of the American Depositary Shares on The Nasdaq Stock Market LLC.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On October 28, 2025, DBV Technologies S.A. (the “Company”) issued a press release announcing financial results and business highlights for the fiscal quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Description
99.1
Press Release dated October 28, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
DBV Technologies S.A.
Date: October 28, 2025
By:
/s/ Virginie Boucinha
Name:
Virginie Boucinha
Title:
Chief Financial Officer
Jul 29, 2025
8-K
00-0000000 true 0001613780 false 0001613780 2025-07-29 2025-07-29 0001613780 us-gaap:CommonStockMember 2025-07-29 2025-07-29 0001613780 dei:AdrMember 2025-07-29 2025-07-29
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2025 Date of Report (Date of earliest event reported)
DBV Technologies S.A. (Exact name of registrant as specified in its charter)
France
001-36697
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
107 avenue de la République 92320 Châtillon France
Not Applicable
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: +33 1 55 42 78 78
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary shares, nominal value €0.10 per share
n/a
The Nasdaq Stock Market LLC *
American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share
The Nasdaq Stock Market LLC
* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On July 29, 2025, DBV Technologies S.A. (the “Company”) issued a press release announcing financial results and business highlights for the fiscal quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press Release issued July 29, 2025
104
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 29, 2025
By:
/s/ Virginie Boucinha
Name:
Virginie Boucinha
Title:
Chief Financial Officer
Apr 30, 2025
8-K
00-0000000 true 0001613780 false 0001613780 2025-04-30 2025-04-30 0001613780 us-gaap:CommonStockMember 2025-04-30 2025-04-30 0001613780 dei:AdrMember 2025-04-30 2025-04-30
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2025 Date of Report (Date of earliest event reported)
DBV Technologies S.A. (Exact name of registrant as specified in its charter)
France
001-36697
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
107 avenue de la République 92320 Châtillon France
Not Applicable
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: +33 1 55 42 78 78
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary shares, nominal value €0.10 per share
n/a
The Nasdaq Stock Market LLC *
American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share
The Nasdaq Stock Market LLC
* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On April 30, 2025, DBV Technologies S.A. (the “Company”) issued a press release announcing financial results and business highlights for the fiscal quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press Release issued April 30, 2025
104
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 30, 2025
By:
/s/ Virginie Boucinha
Name:
Virginie Boucinha
Title:
Chief Financial Officer
See how DBVT stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "DBVT DBV Technologies S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.